Mayo Clinic Cancer Center (MCCC) CCSG Senior Leadership includes the Director, Deputy Director at Large, Deputy Director Clinical Research, Deputy Director Arizona, Deputy Director Florida, Deputy Director Administration, and 3 Associate Directors. There have been a number of changes since the last renewal. Given the size, complexity and geographical locations of our Cancer Center, a Deputy Director at Large was added to aid in the integration of our 3 site Cancer Center. Dr. Edith Perez currently serves in this role. Dr. Ruben Mesa has replaced Dr. Rafael Fonseca as Deputy Director MCCC Arizona as Dr. Fonseca stepped down to assume leadership responsibilities as Chair, Department of Medicine, Mayo Clinic in Arizona. Mr. Brian Nelson has replaced Mr. Michael Pfenning as senior administrator for MCCC. Mr. Pfenning stepped down to assume other leadership responsibilities at Mayo Clinic following 18 years with MCCC. To reflect the size and complexity of MCCC, Mr. Nelson assumed the role of Deputy Director Administration. Dr. Dan Billadeau replaced Dr. Edward Leof as Associate Director for Basic Science. Dr. Steven Russell replaced Dr. Robert Jenkins as Associate Director for Translational Research. Senior Leadership remaining unchanged are Dr. Robert Diasio, Director, Dr. Charies Erlichman, Deputy Director Clinical Research, Dr. Robert Smallridge, Deputy Director Florida, Dr. Gloria Petersen, Associate Director Population Sciences.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-44
Application #
9554070
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Shafik, Hasnaa
Project Start
Project End
Budget Start
2018-03-01
Budget End
2019-02-28
Support Year
44
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Luchtel, Rebecca A; Dasari, Surendra; Oishi, Naoki et al. (2018) Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood 132:1386-1398
Oishi, Naoki; Brody, Garry S; Ketterling, Rhett P et al. (2018) Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. Blood 132:544-547
DuBois, Steven G; Mosse, Yael P; Fox, Elizabeth et al. (2018) Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res 24:6142-6149
Farber, Benjamin A; Lalazar, Gadi; Simon, Elana P et al. (2018) Non coding RNA analysis in fibrolamellar hepatocellular carcinoma. Oncotarget 9:10211-10227
Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430
Dasari, Surendra; Newsom, Sean A; Ehrlicher, Sarah E et al. (2018) Remodeling of skeletal muscle mitochondrial proteome with high-fat diet involves greater changes to ?-oxidation than electron transfer proteins in mice. Am J Physiol Endocrinol Metab 315:E425-E434
Nowsheen, Somaira; Aziz, Khaled; Aziz, Asef et al. (2018) L3MBTL2 orchestrates ubiquitin signalling by dictating the sequential recruitment of RNF8 and RNF168 after DNA damage. Nat Cell Biol 20:455-464
Razidlo, Gina L; Burton, Kevin M; McNiven, Mark A (2018) Interleukin-6 promotes pancreatic cancer cell migration by rapidly activating the small GTPase CDC42. J Biol Chem 293:11143-11153
Wu, Dongyan; Yang, Haitao; Winham, Stacey J et al. (2018) Mediation analysis of alcohol consumption, DNA methylation, and epithelial ovarian cancer. J Hum Genet 63:339-348
Leon-Ferre, Roberto A; Polley, Mei-Yin; Liu, Heshan et al. (2018) Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. Breast Cancer Res Treat 167:89-99

Showing the most recent 10 out of 1129 publications